CA2187752A1 - Utilisation de derives du benzylidene malononitrile dans le traitement de la leucemie - Google Patents

Utilisation de derives du benzylidene malononitrile dans le traitement de la leucemie

Info

Publication number
CA2187752A1
CA2187752A1 CA002187752A CA2187752A CA2187752A1 CA 2187752 A1 CA2187752 A1 CA 2187752A1 CA 002187752 A CA002187752 A CA 002187752A CA 2187752 A CA2187752 A CA 2187752A CA 2187752 A1 CA2187752 A1 CA 2187752A1
Authority
CA
Canada
Prior art keywords
hydroxy
cells
hydrogen
nitro
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002187752A
Other languages
English (en)
Inventor
Chaim M. Roifman
Aviv Gazit
Alexander Levitzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HSC Research and Development LP
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2187752A1 publication Critical patent/CA2187752A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des produits et des méthodes utiles pour traiter des leucémies, en particulier les leucémies lymphoblastiques aiguës. Les composés décrits ici sont efficaces pour inhiber les effets observés dans les leucémies lymphoblastiques aiguës, aussi bien in vivo que in vitro. L'invention concerne également des méthodes pour modifier de tels composés et pour cribler d'autres composés, afin d'identifier des composés additionnels avec des propriétés d'inhibition similaires ou améliorées.
CA002187752A 1994-04-22 1995-04-20 Utilisation de derives du benzylidene malononitrile dans le traitement de la leucemie Abandoned CA2187752A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23171794A 1994-04-22 1994-04-22
US08/231,717 1994-04-22

Publications (1)

Publication Number Publication Date
CA2187752A1 true CA2187752A1 (fr) 1995-11-02

Family

ID=22870385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002187752A Abandoned CA2187752A1 (fr) 1994-04-22 1995-04-20 Utilisation de derives du benzylidene malononitrile dans le traitement de la leucemie

Country Status (5)

Country Link
EP (1) EP0754038A1 (fr)
AU (1) AU2360595A (fr)
CA (1) CA2187752A1 (fr)
IL (1) IL113444A0 (fr)
WO (1) WO1995028922A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06006460A (es) 2003-12-11 2006-08-23 Univ Texas Compuestos para el tratamiento de enfermedades proliferativas celulares.
AU2009268841B2 (en) 2008-07-08 2014-02-06 Board Of Regents, The University Of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (STATS)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026260A1 (fr) * 1993-05-14 1994-11-24 YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM 46 Jabotinsky Street PROCEDES ET COMPOSES INHIBANT LES TROUBLES DE LA PROLIFERATION CELLULAIRE CARACTERISES PAR L'ACTIVITE ANORMALE D'$i(abl)

Also Published As

Publication number Publication date
AU2360595A (en) 1995-11-16
WO1995028922A1 (fr) 1995-11-02
EP0754038A1 (fr) 1997-01-22
IL113444A0 (en) 1995-07-31

Similar Documents

Publication Publication Date Title
WO2023030687A1 (fr) Dérivés de cyclopenta[4,5]furo[3,2-c]pyridine en tant qu'inhibiteurs de ras destinés à être utilisés dans le traitement de maladies hyperprolifératives ou de troubles génétiques
KR20010102514A (ko) 알레르기성 질환 치료용 제이에이케이-3 억제제
TW200918542A (en) Sirtuin modulating compounds
TW200916472A (en) Sirtuin modulating compounds
JP5274444B2 (ja) 特定の耐性腫瘍の治療のためのキナーゼインヒビターの使用
US20040171541A1 (en) Affinity small molecules for the EPO receptor
Chen et al. Design, synthesis, and structure–activity relationship of N-Aryl-N′-(thiophen-2-yl) thiourea derivatives as novel and specific human TLR1/2 agonists for potential cancer immunotherapy
JPH07508000A (ja) １，２，３−トリアゾール及びイミダゾール化合物並びにそれらの抗腫瘍用途
JP2020189857A (ja) イカリイン誘導体
WO2018068666A1 (fr) Inhibiteur de protéine de microtubules
CN108707151A (zh) 嘧啶并-哒嗪酮化合物及其用途
JP2020508313A (ja) 血液悪性腫瘍患者の治療方法
AU2021250199B2 (en) Deuterated oxophenylarsine compound and use thereof
WO2018053373A1 (fr) Utilisations d'inhibiteurs de kinase inductible par un sel (sik) pour traiter l'ostéoporose
Liu et al. Regulation of S100A4 expression via the JAK2–STAT3 pathway in rhomboid-phenotype pulmonary arterial smooth muscle cells exposure to hypoxia
JP2013501808A (ja) アポトーシスを促進し、かつ転移を阻害する方法
JPWO2004093910A1 (ja) ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
CA2187752A1 (fr) Utilisation de derives du benzylidene malononitrile dans le traitement de la leucemie
CN106928229B (zh) 色胺酮及其衍生物在制备hIDO2抑制剂中的用途
CN117159525B (zh) Cert抑制剂在制备治疗急性髓系白血病的药物中的应用
CN112851558B (zh) 2-氰基非那烯酮类化合物及其在白血病治疗中的应用
CN115023240B (zh) 抗癌剂组合物
CA2965898C (fr) Analogues d'acides gras
Üstünel et al. The effects of iloprost and beta3 receptor agonist on TRPA1 and TRPC1 immunreactivityin an experimental lower extremty ischemia-reperfusion injury model
KR20010022050A (ko) 제암제

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued